Glenmark Pharmaceuticals Limited GLENMARK.NS · Stock Open Glenmark Pharmaceuticals Limited in new tab
Glenmark Pharmaceuticals Limited Analysis (GLENMARK.NS)
Is Glenmark Pharmaceuticals Limited a good investment? Glenmark Pharmaceuticals Limited (GLENMARK.NS) is currently trading at 2179.40 INR. Market analysts have a consensus price target of 2496.50 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 45.87. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Glenmark Pharmaceuticals Limited is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is 97.96.
For income investors, Glenmark Pharmaceuticals Limited pays a dividend yield of 0.23%. With a payout ratio of 0%, the dividend appears sustainable.
Investor FAQ
Does Glenmark Pharmaceuticals Limited pay a dividend?
Yes, it pays an annual dividend of 5.00 INR (0.23% yield).
What asset class is Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of 48.26.
Company Profile
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
| Year | Total Dividends |
|---|---|
| ▸2026 |
2.50 INR
|
| Oct. 27, 2026 (estimated) | 2.5000 |
| ▸2025 |
5.00 INR
|
| Oct. 26, 2025 | 2.5000 |
| Oct. 26, 2025 | 2.5000 |
| ▸2024 |
2.50 INR
|
| Oct. 27, 2024 | 2.5000 |
| ▸2023 |
2.50 INR
|
| Oct. 29, 2023 | 2.5000 |
| ▸2022 |
2.50 INR
|
| Oct. 27, 2022 | 2.5000 |
| ▸2021 |
2.50 INR
|
| Oct. 24, 2021 | 2.5000 |
| ▸2020 |
2.50 INR
|
| Oct. 29, 2020 | 2.5000 |
| ▸2019 |
2.00 INR
|
| Oct. 27, 2019 | 2.0000 |
| ▸2018 |
2.00 INR
|
| Oct. 28, 2018 | 2.0000 |
| ▸2017 |
2.00 INR
|
| Oct. 29, 2017 | 2.0000 |
| ▸2016 |
2.00 INR
|
| Aug. 31, 2016 | 2.0000 |
| ▸2015 |
2.00 INR
|
| Oct. 12, 2015 | 2.0000 |
| ▸2014 |
2.00 INR
|
| Aug. 24, 2014 | 2.0000 |
| ▸2013 |
2.00 INR
|
| Sept. 1, 2013 | 2.0000 |
| ▸2012 |
2.00 INR
|
| Sept. 2, 2012 | 2.0000 |
| ▸2011 |
0.40 INR
|
| Sept. 10, 2011 | 0.4000 |
| ▸2010 |
0.40 INR
|
| Oct. 27, 2010 | 0.4000 |
| ▸2009 |
0.40 INR
|
| Oct. 25, 2009 | 0.4000 |
| ▸2007 |
1.50 INR
|
| Dec. 1, 2007 | 0.7000 |
| Jan. 20, 2007 | 0.8000 |
| ▸2006 |
0.70 INR
|
| Feb. 24, 2006 | 0.7000 |
| ▸2005 |
0.70 INR
|
| May 17, 2005 | 0.7000 |
| ▸2004 |
2.60 INR
|
| April 18, 2004 | 2.6000 |
| ▸2003 |
13.00 INR
|
| June 27, 2003 | 13.0000 |
| ▸2002 |
12.00 INR
|
| Oct. 2, 2002 | 12.0000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Glenmark Pharmaceuticals Limited | Oct 26, 2025 | Paid | 2.5 INR |
| Glenmark Pharmaceuticals Limited | Oct 26, 2025 | Paid | 2.5 INR |
| Split Date | Split Ratio to 1 |
|---|---|
| March 4, 2005 | 2.000000 |
| Oct. 23, 2003 | 5.000000 |
| Sept. 10, 2007 | 2.000000 |
Community Discussion